🔗 Share this article

As the United States undertakes unprecedented revisions to its vaccine recommendations, an unexpected name appears in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots during the global health crisis and has focused upon possible deaths following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Vaccine Program

Public health authorities planned to announce radical changes to the pediatric immunization program recently, aligning the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US out of alignment with a large portion of the global community with no evidence for public health gain. This reveal has been postponed until the coming year.

In place of the top vaccines chief, Høeg is set to speak at the gathering. She was just designated acting director of the FDA’s drug evaluation center, the fifth individual to lead the office this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it points to a renewed priority upon rolling back already-approved vaccines at the FDA.

The new acting director has repeatedly called for discontinuing specific pediatric immunization guidelines in the US so as to align more like Denmark's approach, a nation with universal health coverage and a population about the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on immunizations – traditionally the purview of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than drug regulation.

Questions Over Qualifications

The appointee has little discernible experience in pharmaceutical research, regulation or management, which has been typical for previous leaders of the CBER. She has been employed at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the necessary background” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a sizeable institution. She has no expertise in industry regulation.”

Former heads of CBER would “grasp regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she lacks the sort of resume that prior appointees who headed CBER have had.”

This division has an immense workload at the agency, she pointed out.

“The public just focuses on the new drug program, but the off-patent medication office clears thousands of generic drugs. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one must be supervised,” Dr. Woodcock explained. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership aspect to the position, which oversees in excess of 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” she concluded.

Response and Controversial Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a representative said that the “questions are based on inaccurate premises”.

“This background matches the responsibilities of her position,” the official stated, pointing to the period Høeg spent counseling the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious expedited therapy clearance system that reportedly concerned her preceding directors. “By what process are these therapies being chosen for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards more relaxed rules of most medications, with the exception of shots.”

Public History on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if problematic, past, critics said. She released a analysis using unverified public submissions to determine the frequency of heart inflammation following COVID-19 vaccination. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the incoming administration featured revising guidelines for new vaccines and ending “unnecessary” immunizations, she said following the vote on a podcast. At the agency, Dr. Høeg has according to sources proposed preventing teenage boys from getting Covid vaccines.

“She’s an all-around dogmatist who commences with her preconceived notions and works backwards to accommodate the science in a extremely deceptive, fraudulent fashion,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined other contrarians, {like|